{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:38:28Z","timestamp":1793335108743,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017168","name":"Barcelona Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017168","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eclinm.2020.100720","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T05:01:45Z","timestamp":1611032505000},"page":"100720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"special_numbering":"C","title":["The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9812-050X","authenticated-orcid":false,"given":"Carlos","family":"Chaccour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Casellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-2841","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Blanco-Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Fernandez-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ruiz-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ann","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Rodr\u00edguez-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Jord\u00e1n-Iborra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Brew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Carmona-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gir\u00e1ldez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Laso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Gabald\u00f3n-Figueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Doba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.Regina","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Sch\u00f6ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Sadaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Fern\u00e1ndez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2020.100720_bib0001","unstructured":"WHO. COVID-19 Weekly epidemiological update - 15 December 2020. Available at https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update\u201415-december-2020 (Accessed December 21, 2020)."},{"issue":"8","key":"10.1016\/j.eclinm.2020.100720_bib0002","first-page":"732","article-title":"Difficult to determine herd immunity threshold for COVID-19","volume":"324","author":"Rubin","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eclinm.2020.100720_bib0003","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41577-020-00451-5","article-title":"COVID-19 herd immunity: where are we?","volume":"20","author":"Fontanet","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2020.100720_bib0004","unstructured":"WHO. Newsroom - coronavirus disease (COVID-19): vaccines. Available at https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-(covid-19)-vaccines (accessed December 21, 2020)."},{"issue":"3","key":"10.1016\/j.eclinm.2020.100720_bib0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin alpha\/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.eclinm.2020.100720_bib0006","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.eclinm.2020.100720_bib0007","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2020.100720_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2020.100720_bib0009","unstructured":"Chaccour C, Brew J, Garcia-Basteiro A. Ivermectin and COVID-19: how a flawed database shaped the pandemic response of several Latin-American countries. Available at: https:\/\/www.isglobal.org\/en\/healthisglobal\/-\/custom-blog-portlet\/ivermectin-and-covid-19-how-a-flawed-database-shaped-the-covid-19-response-of-several-latin-american-countries\/2877257\/0 (Accessed Nov 2020)."},{"key":"10.1016\/j.eclinm.2020.100720_bib0010","unstructured":"Clinical trial of ivermectin plus doxycycline for the treatment of confirmed COVID-19 infection. NCT04523831. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT04523831 (accessed Nov 2020)."},{"key":"10.1016\/j.eclinm.2020.100720_bib0011","article-title":"A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness","author":"Ahmed","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.eclinm.2020.100720_bib0012","doi-asserted-by":"crossref","unstructured":"Krolewiecki A, Lifschitz A, Moragas M, et\u00a0al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial. http:\/\/dx.doi.org\/10.2139\/ssrn.3714649 (accessed Nov 2020).","DOI":"10.2139\/ssrn.3714649"},{"key":"10.1016\/j.eclinm.2020.100720_bib0013","article-title":"Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON study","author":"Rajter","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.eclinm.2020.100720_bib0014","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s13063-020-04421-z","volume":"21","author":"Chaccour","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2020.100720_bib0015","unstructured":"European_Medicines_Agency. EMA decision of 18 December 2012 on the granting of a product-specific waiver for ivermectin. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500138600.pdf (accessed july 2015)."},{"key":"10.1016\/j.eclinm.2020.100720_bib0016","article-title":"Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation?","author":"Rhee","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2020.100720_bib0017","article-title":"SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of coronavirus viral load from 66 studies","author":"Benefield","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2020.100720_bib0018","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","author":"He","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.eclinm.2020.100720_bib0019","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eclinm.2020.100720_bib0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ijo.2011.100","article-title":"Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity","volume":"36","author":"Gomez-Ambrosi","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.eclinm.2020.100720_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104805","article-title":"Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses","author":"Bray","year":"2020","journal-title":"Antiviral Res"},{"issue":"4","key":"10.1016\/j.eclinm.2020.100720_bib0022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"7826","key":"10.1016\/j.eclinm.2020.100720_bib0023","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2020.100720_bib0024","article-title":"Anti-COVID-19 efficacy of ivermectin in the golden hamster","author":"de Melo","year":"2020","journal-title":"bioRxiv"},{"issue":"10","key":"10.1016\/j.eclinm.2020.100720_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241104","article-title":"Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders","volume":"15","author":"Marklund","year":"2020","journal-title":"PLoS One"},{"issue":"54","key":"10.1016\/j.eclinm.2020.100720_bib0026","doi-asserted-by":"crossref","first-page":"eabe0240","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"R\u00f6ltgen","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2020.100720_bib0027","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5802\/crbiol.8","article-title":"A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications","volume":"343","author":"Changeux","year":"2020","journal-title":"C R Biol"},{"issue":"13","key":"10.1016\/j.eclinm.2020.100720_bib0028","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/acschemneuro.0c00249","article-title":"Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia","volume":"11","author":"Torabi","year":"2020","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"10.1016\/j.eclinm.2020.100720_bib0029","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/jdv.14437","article-title":"Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea","volume":"31","author":"Schaller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.eclinm.2020.100720_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13555-017-0176-3","article-title":"Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models","volume":"7","author":"Thibaut de M\u00e9nonville","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"10.1016\/j.eclinm.2020.100720_bib0031","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.4049\/jimmunol.1302005","article-title":"Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease","volume":"191","author":"Kahlenberg","year":"2013","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.eclinm.2020.100720_bib0032","doi-asserted-by":"crossref","first-page":"AB172","DOI":"10.1016\/j.jaad.2015.02.705","article-title":"MeTC7, a novel vitamin D receptor (VDR) antagonist, induces cytotoxicity in metastatic melanoma cell lines and inhibits importin-mediated VDR nuclear transport and signaling","volume":"72","author":"Han","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.eclinm.2020.100720_bib0033","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"issue":"49","key":"10.1016\/j.eclinm.2020.100720_bib0034","doi-asserted-by":"crossref","first-page":"40901","DOI":"10.1074\/jbc.M509347200","article-title":"Importin 4 is responsible for ligand-independent nuclear translocation of vitamin D receptor","volume":"280","author":"Miyauchi","year":"2005","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.eclinm.2020.100720_bib0035","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2217\/fmb.09.87","article-title":"The vitamin D-antimicrobial peptide pathway and its role in protection against infection","volume":"4","author":"Gombart","year":"2009","journal-title":"Fut Microbiol"},{"issue":"1","key":"10.1016\/j.eclinm.2020.100720_bib0036","doi-asserted-by":"crossref","first-page":"17073","DOI":"10.1038\/s41598-020-74084-y","article-title":"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats","volume":"10","author":"Chaccour","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.eclinm.2020.100720_bib0037","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Liu","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2020.100720_bib0038","article-title":"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis","author":"Cevik","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.eclinm.2020.100720_bib0039","article-title":"Ct values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load","author":"Dahdouh","year":"2020","journal-title":"J Infect"}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020304648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020304648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:05:15Z","timestamp":1762887915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537020304648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"alternative-id":["S2589537020304648"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100720","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-116547\/v1","asserted-by":"object"}]},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100720"}}